Robert Aslanian

List of Publications by Year
in descending order

61	1,196	331670	434195
papers	citations	21 h-index	31 g-index

72	72	72	1066
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma. ACS Medicinal Chemistry Letters, 2018, 9, 679-684.	2.8	10
2	The synthesis of 2,3,6-trisubstituted 1-oxo-1,2-dihydroisoquinolines as potent CRTh 2 antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5344-5348.	2.2	6
3	Synthesis of novel anti-inflammatory steroidal macrocycles using ring closing metathesis reaction. Tetrahedron Letters, 2015, 56, 636-638.	1.4	4
4	Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like properties. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1615-1620.	2.2	6
5	Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3609-3613.	2.2	13
6	Conformation of gem-disubstituted alkylarylpiperidines and their implication in design and synthesis of a conformationally-rigidified NK1 antagonist. Tetrahedron Letters, 2013, 54, 6199-6203.	1.4	3
7	The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 466-471.	2.2	23
8	Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3262-3266.	2.2	20
9	Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors. ACS Medicinal Chemistry Letters, 2012, 3, 100-105.	2.8	13
10	Efficient and regioselective synthesis of pyrimido[5,4-d]pyrimidine-2,4,6,8(1H,3H,5H,7H)-tetraones with diversified substitutions. Tetrahedron Letters, 2012, 53, 7154-7158.	1.4	10
11	Steroidal C-21 heteroaryl thioethers (Part 2): Discovery of orally bioavailable selective glucocorticoid receptor modulators (dissociated steroids). Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1086-1090.	2.2	6
12	Efficient synthesis and reaction pathway studies of novel fused morpholine oxadiazolines for use as gamma secretase modulators. Tetrahedron Letters, 2012, 53, 6451-6455.	1.4	8
13	Synthesis and SAR Studies of Fused Oxadiazines as Î³-Secretase Modulators for Treatment of Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2012, 3, 931-935.	2.8	34
14	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Medicinal Chemistry Letters, 2012, 3, 63-68.	2.8	22
15	A three-step protocol for lead optimization: Quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 65-70.	2.2	20
16	SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 854-858.	2.2	12
17	Discovery of oxazole-based PDE4 inhibitors with picomolar potency. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2594-2597.	2.2	21
18	Fused bicycles as arylketone bioisosteres leading to potent, orally active thiadiazole H3 antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3354-3357.	2.2	4

#	Article	IF	Citations
19	Steroidal C-21 heteroaryl thioethers. Part 3: Pregn-4-eno-[3,2-c]pyrazole fused A ring modified steroids as selective glucocorticoid receptor modulators (dissociated steroids). Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3291-3295.	2.2	4
20	Discovery of a Potent Pyrazolopyridine Series of Î³-Secretase Modulators. ACS Medicinal Chemistry Letters, 2011, 2, 471-476.	2.8	33
21	Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Medicinal Chemistry Letters, 2011, 2, 171-176.	2.8	20
22	Steroidal C-21 mercapto derivatives as dissociated steroids: Discovery of an inhaled dissociated steroid. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6343-6347.	2.2	16
23	Discovery of a series of potent arylthiadiazole H3 antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 861-864.	2.2	11
24	Discovery of fused 5,6-bicyclic heterocycles as Î³-secretase modulators. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 664-669.	2.2	26
25	The Discovery of Pyridone and Pyridazone Heterocycles as Î³-Secretase Modulators. ACS Medicinal Chemistry Letters, 2010, 1, 184-187.	2.8	32
26	The synthesis and structureâ€“activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5004-5008.	2.2	8
27	Discovery of a series of potent, orally active Î±,Î±-disubstituted piperidine NK1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6313-6315.	2.2	9
28	New Applications of PhI(OAc)2 in Synthesis: Total Synthesis and SAR Development of Potent Antitumor Natural Product Psymberin/Irciniastatin A. Synthesis, 2009, 2009, 2855-2872.	2.3	24
29	Spiro-piperidine azetidinones as potent TRPV1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 783-787.	2.2	14
30	The Discovery of Potent Antitumor Agent C11-Deoxypsymberin/irciniastatin A: Total Synthesis and Biology of Advanced Psymberin Analogs. Organic Letters, 2009, 11, 867-870.	4.6	40
31	Synthesis of seco-psymberin/irciniastatin A: the discovery of a novel PhI(OAc)2 mediated cascade cyclization reaction. Tetrahedron Letters, 2008, 49, 3592-3595.	1.4	18
32	Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5032-5036.	2.2	15
33	A Useful Pd-Catalyzed Negishi Coupling Approach to Benzylic Sulfonamide Derivatives. Organic Letters, 2008, 10, 2517-2520.	4.6	35
34	Oxidation of Methyl Heteroaryls with Molecular Oxygen: A Facile Synthesis of 2-[N-(tert-Butoxycarbonyl)amino]-4-pyridinecarbaldehyde. Synthesis, 2007, 2007, 2529-2533.	2.3	4
35	Oxidative entry to Î±-oxy N-acyl aminals and hemiaminals: efficient formation of 2-(N-acylaminal) substituted tetrahydropyrans. Tetrahedron Letters, 2007, 48, 1967-1971.	1.4	26
36	Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5150-5154.	2.2	32

#	Article	IF	Citations
37	The Total Synthesis of Psymberin. Organic Letters, 2007, 9, 2597-2600.	4.6	56
38	Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 395-399.	2.2	10
39	Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 989-994.	2.2	20
40	Two complementary, diversity-driven asymmetric syntheses of a 2,2-disubstituted piperidine NK1 antagonist. Tetrahedron: Asymmetry, 2006, 17, 2596-2598.	1.8	9
41	Efficient one-pot formation of 4-N-substituted 2,4-dihydro-3H-1,2,4-triazolin-3-ones from primary amines using Nâ€²-(ethoxymethylene)hydrazinecarboxylic acid methyl ester. Tetrahedron Letters, 2006, 47, 6743-6746.	1.4	6
42	The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1375-1378.	2.2	28
43	The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: Antagonists versus agonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3020-3023.	2.2	17
44	Manipulation of N,O-Nucleophilicity: Efficient Formation of 4-N-Substituted 2,4-Dihydro-3H-1,2,4-triazolin-3-ones.. ChemInform, 2005, 36, no.	0.0	0
45	Manipulation of N,O-Nucleophilicity:â€‰ Efficient Formation of 4-N-Substituted 2,4-Dihydro-3H-1,2,4-Triazolin-3-ones. Organic Letters, 2004, 6, 4795-4798.	4.6	10
46	Recent Progress in Histamine H3 Receptor Chemistry. Annual Reports in Medicinal Chemistry, 2004, 39, 57-66.	0.9	7
47	The Synthesis of Substituted Fluorenes as Novel Non-imidazole Histamine H3 Inhibitors.. ChemInform, 2003, 34, no.	0.0	0
48	Identification of a Dual Histamine H1/H3 Receptor Ligand Based on the H1 Antagonist Chlorpheniramine.. ChemInform, 2003, 34, no.	0.0	0
49	Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1959-1961.	2.2	34
50	Pharmacological Characterization of the Novel Histamine H3-Receptor Antagonist N-(3,5-Dichlorophenyl)-Nâ€²-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 1037-1044.	2.5	39
51	Coordination of Histamine H₃ Receptor Antagonists with Human Adrenal Cytochrome P450 Enzymes. Pharmacology, 2002, 66, 128-135.	2.2	76
52	Structureâ€“Activity relationships of oxime neurokinin antagonists: oxime modifications. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 833-836.	2.2	3
53	Identification of a novel, orally bioavailable histamine H 3 receptor antagonist based on the 4-benzyl-(1) Tj ETQq1 1 0.784314 rgBT /O	2.2	28
54	The Synthesis of Substituted Fluorenes as Novel Non-Imidazole Histamine H3 Inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2643-2646.	2.2	15

#	Article	IF	Citations
55	An asymmetric synthesis of the novel H3 agonist (+)-(3R,4R)-3-(4-imidazolyl)-4-methylpyrrolidine dihydrochloride (Sch 50971). Tetrahedron: Asymmetry, 2000, 11, 3867-3871.	1.8	27
56	The design and synthesis of novel NK1/NK2 dual antagonists. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2329-2332.	2.2	33
57	Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivo. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 243-248.	2.2	14
58	4- [(1H - imidazol - 4 - YL) methyl] benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2263-2268.	2.2	14
59	A Novel Pyrrolidine Analog of Histamine as a Potent, Highly Selective Histamine H3 Receptor Agonist. Journal of Medicinal Chemistry, 1995, 38, 1593-1599.	6.4	40
60	Synthesis of protected allylamines via palladium-catalyzed amide addition to allylic substrates. Tetrahedron Letters, 1985, 26, 1749-1752.	1.4	74
61	Facile route to 1-phosphoryl- and 1-sulfonyl-1,3-dienes via palladium-catalyzed elimination of allylic acetates. Tetrahedron Letters, 1984, 25, 5719-5722.	1.4	34